- IBDEI1G5 ; ; 01-FEB-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,23400,1,4,0)
- ;;=4^I95.9
- ;;^UTILITY(U,$J,358.3,23400,2)
- ;;=^5008080
- ;;^UTILITY(U,$J,358.3,23401,0)
- ;;=Z51.81^^78^1009^25
- ;;^UTILITY(U,$J,358.3,23401,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23401,1,3,0)
- ;;=3^Therapeutic Drug Level Monitoring
- ;;^UTILITY(U,$J,358.3,23401,1,4,0)
- ;;=4^Z51.81
- ;;^UTILITY(U,$J,358.3,23401,2)
- ;;=^5063064
- ;;^UTILITY(U,$J,358.3,23402,0)
- ;;=D68.51^^78^1009^1
- ;;^UTILITY(U,$J,358.3,23402,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23402,1,3,0)
- ;;=3^Activated Protein C Resistance
- ;;^UTILITY(U,$J,358.3,23402,1,4,0)
- ;;=4^D68.51
- ;;^UTILITY(U,$J,358.3,23402,2)
- ;;=^5002358
- ;;^UTILITY(U,$J,358.3,23403,0)
- ;;=I82.402^^78^1009^2
- ;;^UTILITY(U,$J,358.3,23403,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23403,1,3,0)
- ;;=3^Acute Embolism/Thrombos Deep Veins Left Lower Extremity
- ;;^UTILITY(U,$J,358.3,23403,1,4,0)
- ;;=4^I82.402
- ;;^UTILITY(U,$J,358.3,23403,2)
- ;;=^5007855
- ;;^UTILITY(U,$J,358.3,23404,0)
- ;;=I82.401^^78^1009^3
- ;;^UTILITY(U,$J,358.3,23404,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23404,1,3,0)
- ;;=3^Acute Embolism/Thrombos Deep Veins Right Lower Extremity
- ;;^UTILITY(U,$J,358.3,23404,1,4,0)
- ;;=4^I82.401
- ;;^UTILITY(U,$J,358.3,23404,2)
- ;;=^5007854
- ;;^UTILITY(U,$J,358.3,23405,0)
- ;;=I82.890^^78^1009^4
- ;;^UTILITY(U,$J,358.3,23405,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23405,1,3,0)
- ;;=3^Acute Embolism/Thrombosis of Specified Veins
- ;;^UTILITY(U,$J,358.3,23405,1,4,0)
- ;;=4^I82.890
- ;;^UTILITY(U,$J,358.3,23405,2)
- ;;=^5007938
- ;;^UTILITY(U,$J,358.3,23406,0)
- ;;=D68.61^^78^1009^6
- ;;^UTILITY(U,$J,358.3,23406,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23406,1,3,0)
- ;;=3^Antiphospholipid Syndrome
- ;;^UTILITY(U,$J,358.3,23406,1,4,0)
- ;;=4^D68.61
- ;;^UTILITY(U,$J,358.3,23406,2)
- ;;=^185421
- ;;^UTILITY(U,$J,358.3,23407,0)
- ;;=I63.50^^78^1009^7
- ;;^UTILITY(U,$J,358.3,23407,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23407,1,3,0)
- ;;=3^Cerebral Infarction d/t Occls/Stenos of Cereb Artery
- ;;^UTILITY(U,$J,358.3,23407,1,4,0)
- ;;=4^I63.50
- ;;^UTILITY(U,$J,358.3,23407,2)
- ;;=^5007343
- ;;^UTILITY(U,$J,358.3,23408,0)
- ;;=I82.91^^78^1009^8
- ;;^UTILITY(U,$J,358.3,23408,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23408,1,3,0)
- ;;=3^Chronic Embolism/Thrombosis Unspec Vein
- ;;^UTILITY(U,$J,358.3,23408,1,4,0)
- ;;=4^I82.91
- ;;^UTILITY(U,$J,358.3,23408,2)
- ;;=^5007941
- ;;^UTILITY(U,$J,358.3,23409,0)
- ;;=I25.9^^78^1009^10
- ;;^UTILITY(U,$J,358.3,23409,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23409,1,3,0)
- ;;=3^Chronic Ischemic Heart Disease,Unspec
- ;;^UTILITY(U,$J,358.3,23409,1,4,0)
- ;;=4^I25.9
- ;;^UTILITY(U,$J,358.3,23409,2)
- ;;=^5007144
- ;;^UTILITY(U,$J,358.3,23410,0)
- ;;=D68.9^^78^1009^11
- ;;^UTILITY(U,$J,358.3,23410,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23410,1,3,0)
- ;;=3^Coagulation Defect,Unspec
- ;;^UTILITY(U,$J,358.3,23410,1,4,0)
- ;;=4^D68.9
- ;;^UTILITY(U,$J,358.3,23410,2)
- ;;=^5002364
- ;;^UTILITY(U,$J,358.3,23411,0)
- ;;=D68.8^^78^1009^12
- ;;^UTILITY(U,$J,358.3,23411,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23411,1,3,0)
- ;;=3^Coagulation Defects,Other Spec
- ;;^UTILITY(U,$J,358.3,23411,1,4,0)
- ;;=4^D68.8
- ;;^UTILITY(U,$J,358.3,23411,2)
- ;;=^5002363
- ;;^UTILITY(U,$J,358.3,23412,0)
- ;;=D68.318^^78^1009^13
- ;;^UTILITY(U,$J,358.3,23412,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,23412,1,3,0)
- ;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1G5 3776 printed Feb 18, 2025@23:34:25 Page 2
- IBDEI1G5 ; ; 01-FEB-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,23400,1,4,0)
- +2 ;;=4^I95.9
- +3 ;;^UTILITY(U,$J,358.3,23400,2)
- +4 ;;=^5008080
- +5 ;;^UTILITY(U,$J,358.3,23401,0)
- +6 ;;=Z51.81^^78^1009^25
- +7 ;;^UTILITY(U,$J,358.3,23401,1,0)
- +8 ;;=^358.31IA^4^2
- +9 ;;^UTILITY(U,$J,358.3,23401,1,3,0)
- +10 ;;=3^Therapeutic Drug Level Monitoring
- +11 ;;^UTILITY(U,$J,358.3,23401,1,4,0)
- +12 ;;=4^Z51.81
- +13 ;;^UTILITY(U,$J,358.3,23401,2)
- +14 ;;=^5063064
- +15 ;;^UTILITY(U,$J,358.3,23402,0)
- +16 ;;=D68.51^^78^1009^1
- +17 ;;^UTILITY(U,$J,358.3,23402,1,0)
- +18 ;;=^358.31IA^4^2
- +19 ;;^UTILITY(U,$J,358.3,23402,1,3,0)
- +20 ;;=3^Activated Protein C Resistance
- +21 ;;^UTILITY(U,$J,358.3,23402,1,4,0)
- +22 ;;=4^D68.51
- +23 ;;^UTILITY(U,$J,358.3,23402,2)
- +24 ;;=^5002358
- +25 ;;^UTILITY(U,$J,358.3,23403,0)
- +26 ;;=I82.402^^78^1009^2
- +27 ;;^UTILITY(U,$J,358.3,23403,1,0)
- +28 ;;=^358.31IA^4^2
- +29 ;;^UTILITY(U,$J,358.3,23403,1,3,0)
- +30 ;;=3^Acute Embolism/Thrombos Deep Veins Left Lower Extremity
- +31 ;;^UTILITY(U,$J,358.3,23403,1,4,0)
- +32 ;;=4^I82.402
- +33 ;;^UTILITY(U,$J,358.3,23403,2)
- +34 ;;=^5007855
- +35 ;;^UTILITY(U,$J,358.3,23404,0)
- +36 ;;=I82.401^^78^1009^3
- +37 ;;^UTILITY(U,$J,358.3,23404,1,0)
- +38 ;;=^358.31IA^4^2
- +39 ;;^UTILITY(U,$J,358.3,23404,1,3,0)
- +40 ;;=3^Acute Embolism/Thrombos Deep Veins Right Lower Extremity
- +41 ;;^UTILITY(U,$J,358.3,23404,1,4,0)
- +42 ;;=4^I82.401
- +43 ;;^UTILITY(U,$J,358.3,23404,2)
- +44 ;;=^5007854
- +45 ;;^UTILITY(U,$J,358.3,23405,0)
- +46 ;;=I82.890^^78^1009^4
- +47 ;;^UTILITY(U,$J,358.3,23405,1,0)
- +48 ;;=^358.31IA^4^2
- +49 ;;^UTILITY(U,$J,358.3,23405,1,3,0)
- +50 ;;=3^Acute Embolism/Thrombosis of Specified Veins
- +51 ;;^UTILITY(U,$J,358.3,23405,1,4,0)
- +52 ;;=4^I82.890
- +53 ;;^UTILITY(U,$J,358.3,23405,2)
- +54 ;;=^5007938
- +55 ;;^UTILITY(U,$J,358.3,23406,0)
- +56 ;;=D68.61^^78^1009^6
- +57 ;;^UTILITY(U,$J,358.3,23406,1,0)
- +58 ;;=^358.31IA^4^2
- +59 ;;^UTILITY(U,$J,358.3,23406,1,3,0)
- +60 ;;=3^Antiphospholipid Syndrome
- +61 ;;^UTILITY(U,$J,358.3,23406,1,4,0)
- +62 ;;=4^D68.61
- +63 ;;^UTILITY(U,$J,358.3,23406,2)
- +64 ;;=^185421
- +65 ;;^UTILITY(U,$J,358.3,23407,0)
- +66 ;;=I63.50^^78^1009^7
- +67 ;;^UTILITY(U,$J,358.3,23407,1,0)
- +68 ;;=^358.31IA^4^2
- +69 ;;^UTILITY(U,$J,358.3,23407,1,3,0)
- +70 ;;=3^Cerebral Infarction d/t Occls/Stenos of Cereb Artery
- +71 ;;^UTILITY(U,$J,358.3,23407,1,4,0)
- +72 ;;=4^I63.50
- +73 ;;^UTILITY(U,$J,358.3,23407,2)
- +74 ;;=^5007343
- +75 ;;^UTILITY(U,$J,358.3,23408,0)
- +76 ;;=I82.91^^78^1009^8
- +77 ;;^UTILITY(U,$J,358.3,23408,1,0)
- +78 ;;=^358.31IA^4^2
- +79 ;;^UTILITY(U,$J,358.3,23408,1,3,0)
- +80 ;;=3^Chronic Embolism/Thrombosis Unspec Vein
- +81 ;;^UTILITY(U,$J,358.3,23408,1,4,0)
- +82 ;;=4^I82.91
- +83 ;;^UTILITY(U,$J,358.3,23408,2)
- +84 ;;=^5007941
- +85 ;;^UTILITY(U,$J,358.3,23409,0)
- +86 ;;=I25.9^^78^1009^10
- +87 ;;^UTILITY(U,$J,358.3,23409,1,0)
- +88 ;;=^358.31IA^4^2
- +89 ;;^UTILITY(U,$J,358.3,23409,1,3,0)
- +90 ;;=3^Chronic Ischemic Heart Disease,Unspec
- +91 ;;^UTILITY(U,$J,358.3,23409,1,4,0)
- +92 ;;=4^I25.9
- +93 ;;^UTILITY(U,$J,358.3,23409,2)
- +94 ;;=^5007144
- +95 ;;^UTILITY(U,$J,358.3,23410,0)
- +96 ;;=D68.9^^78^1009^11
- +97 ;;^UTILITY(U,$J,358.3,23410,1,0)
- +98 ;;=^358.31IA^4^2
- +99 ;;^UTILITY(U,$J,358.3,23410,1,3,0)
- +100 ;;=3^Coagulation Defect,Unspec
- +101 ;;^UTILITY(U,$J,358.3,23410,1,4,0)
- +102 ;;=4^D68.9
- +103 ;;^UTILITY(U,$J,358.3,23410,2)
- +104 ;;=^5002364
- +105 ;;^UTILITY(U,$J,358.3,23411,0)
- +106 ;;=D68.8^^78^1009^12
- +107 ;;^UTILITY(U,$J,358.3,23411,1,0)
- +108 ;;=^358.31IA^4^2
- +109 ;;^UTILITY(U,$J,358.3,23411,1,3,0)
- +110 ;;=3^Coagulation Defects,Other Spec
- +111 ;;^UTILITY(U,$J,358.3,23411,1,4,0)
- +112 ;;=4^D68.8
- +113 ;;^UTILITY(U,$J,358.3,23411,2)
- +114 ;;=^5002363
- +115 ;;^UTILITY(U,$J,358.3,23412,0)
- +116 ;;=D68.318^^78^1009^13
- +117 ;;^UTILITY(U,$J,358.3,23412,1,0)
- +118 ;;=^358.31IA^4^2
- +119 ;;^UTILITY(U,$J,358.3,23412,1,3,0)
- +120 ;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
